JP6851965B2 - 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 - Google Patents

疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 Download PDF

Info

Publication number
JP6851965B2
JP6851965B2 JP2017516948A JP2017516948A JP6851965B2 JP 6851965 B2 JP6851965 B2 JP 6851965B2 JP 2017516948 A JP2017516948 A JP 2017516948A JP 2017516948 A JP2017516948 A JP 2017516948A JP 6851965 B2 JP6851965 B2 JP 6851965B2
Authority
JP
Japan
Prior art keywords
seq
group
inflammation
administration
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017516948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500274A5 (https=
JP2018500274A (ja
Inventor
サハイ バートナガール ラジェンドラ
サハイ バートナガール ラジェンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2018500274A publication Critical patent/JP2018500274A/ja
Publication of JP2018500274A5 publication Critical patent/JP2018500274A5/ja
Application granted granted Critical
Publication of JP6851965B2 publication Critical patent/JP6851965B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017516948A 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 Active JP6851965B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055982P 2014-09-26 2014-09-26
US62/055,982 2014-09-26
PCT/US2015/052467 WO2016049580A2 (en) 2014-09-26 2015-09-25 Inhibitors of nf kappa-b activity for treatment of diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021036502A Division JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Publications (3)

Publication Number Publication Date
JP2018500274A JP2018500274A (ja) 2018-01-11
JP2018500274A5 JP2018500274A5 (https=) 2019-05-09
JP6851965B2 true JP6851965B2 (ja) 2021-03-31

Family

ID=55582262

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017516948A Active JP6851965B2 (ja) 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2021036502A Active JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021036502A Active JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Country Status (7)

Country Link
US (5) US10030048B2 (https=)
EP (1) EP3197474B1 (https=)
JP (3) JP6851965B2 (https=)
CN (2) CN114432423A (https=)
AU (2) AU2015320341B2 (https=)
CA (1) CA2999711A1 (https=)
WO (1) WO2016049580A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
CA3191058A1 (en) * 2020-08-28 2022-03-03 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU215581B (hu) * 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
US5635482A (en) 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US20030077825A1 (en) 1994-07-22 2003-04-24 Bhatnagar Rajendra S. Structures useful for bone engineering and methods
US5354736A (en) 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5674848A (en) 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
WO1991002537A1 (en) 1989-08-14 1991-03-07 The Regents Of The University Of California Synthetic peptides that enhance cell binding
WO1995016709A2 (en) * 1993-12-13 1995-06-22 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
US5661127A (en) 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
WO1998009620A1 (en) * 1996-09-05 1998-03-12 Research Development Foundation INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001082773A2 (en) 2000-04-28 2001-11-08 The Regents Of The University Of California Structures useful for bone engineering and methods
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
PT1678209E (pt) * 2003-10-07 2011-06-30 Yeda Res & Dev Anticorpos para a nik, a sua preparação e a sua utilização
EP1869206A4 (en) * 2005-03-02 2011-08-10 Einstein Coll Med ENZYME SENSORS WITH ENVIRONMENTAL SENSITIVE OR FLUORESCENT LABELS AND APPLICATIONS THEREOF
WO2006133027A2 (en) 2005-06-03 2006-12-14 Bhatnagar Rajendra S Methods for immobilizing molecules on surfaces
US20060293228A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
US20060293227A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
CA2722754A1 (en) 2007-04-27 2009-01-29 The University Of Toledo Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
WO2009013753A1 (en) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
EP2124060A1 (en) * 2008-05-23 2009-11-25 ETH Zurich Method for high throughput peptide/protein assay generation and assays generated therewith
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
WO2010051064A1 (en) * 2008-10-30 2010-05-06 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT NFκB ACTIVITY
AU2010253834B2 (en) * 2009-05-27 2013-12-19 Dana-Farber Cancer Institute, Inc. Inhibition 0f inflammation using antagonists of MUC1
WO2011087768A1 (en) * 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
JP2013176368A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN103223175B (zh) * 2013-05-23 2015-07-22 中国人民解放军第三军医大学第三附属医院 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用
US20160000682A1 (en) 2014-07-02 2016-01-07 Geoffrey Brooks Consultants Llc Peptide-Based Compositions and Methods of Use
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
DE202018003082U1 (de) 2018-07-03 2019-10-07 Ergon International Gmbh Fahrradsattel
CA3191058A1 (en) 2020-08-28 2022-03-03 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Also Published As

Publication number Publication date
CA2999711A1 (en) 2016-03-31
JP2021091728A (ja) 2021-06-17
JP7184946B2 (ja) 2022-12-06
US20260015386A1 (en) 2026-01-15
US10030048B2 (en) 2018-07-24
EP3197474B1 (en) 2023-06-07
WO2016049580A2 (en) 2016-03-31
US11773135B2 (en) 2023-10-03
JP2018500274A (ja) 2018-01-11
US20240083941A1 (en) 2024-03-14
EP3197474A2 (en) 2017-08-02
EP3197474A4 (en) 2018-08-22
US12325760B2 (en) 2025-06-10
AU2021221579B2 (en) 2025-01-23
JP2023010979A (ja) 2023-01-20
US20170051012A1 (en) 2017-02-23
WO2016049580A3 (en) 2016-05-19
CN106999535B (zh) 2021-12-21
US11174286B2 (en) 2021-11-16
CN106999535A (zh) 2017-08-01
US20220106359A1 (en) 2022-04-07
CN114432423A (zh) 2022-05-06
AU2021221579A1 (en) 2021-09-16
US20180298055A1 (en) 2018-10-18
AU2015320341A1 (en) 2017-05-04
AU2015320341B2 (en) 2021-05-27
EP3197474C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US12325760B2 (en) Inhibitors of NF kappa-B activity for treatment of diseases and disorders
ES2777652T3 (es) Modulación de la actividad de proneurotrofinas
JP2023022318A (ja) ペプチドｗｋｄｅａｇｋｐｌｖｋを含む組成物
KR101342488B1 (ko) 테트라펩타이드 및 이를 함유하는 피부노화 방지 및 항염효능의 화장료 조성물
JP5700641B2 (ja) メタスチン誘導体およびその用途
US9155795B2 (en) CXCR4 receptor compounds
EP4324841A1 (en) Cell-penetrating peptide, anti-cancer peptide, and pharmaceutical composition for preventing or treating cancer, comprising same
JP2020515294A (ja) アブラナ科のタンパク質抽出物およびその使用
US20220395553A1 (en) Cxcr4 antagonist peptides
JP6710416B2 (ja) 炎症性皮膚疾患の予防又は治療剤
CN102807609B (zh) 一种预防和/或治疗疼痛的多肽及其应用
JP7464310B2 (ja) Ｗｎｔシグナル伝達経路の抑制剤
HK40074479A (en) Inhibitors of nf kappa-b activity for treatment of diseases and disorders
Zhang et al. Tetrapeptides derived from black bean enhance osteogenesis and alleviate ovariectomy-induced bone loss via activation of BMP-2/Smad signaling
US10369187B2 (en) Peptide regulators of JNK family kinases
WO2025150453A1 (ja) 変形性関節症の予防又は治療剤
CN119874872A (zh) 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用
Holzenberger PL8 IGF-1 receptor in adults: What the cell-specific knockouts tell us

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210310

R150 Certificate of patent or registration of utility model

Ref document number: 6851965

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250